Compare ALEC & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALEC | QTRX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.7M | 306.0M |
| IPO Year | 2019 | 2017 |
| Metric | ALEC | QTRX |
|---|---|---|
| Price | $2.00 | $3.58 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | $4.83 | ★ $11.33 |
| AVG Volume (30 Days) | ★ 718.7K | 685.7K |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $21,045,000.00 | ★ $37,632,000.00 |
| Revenue This Year | $18.36 | $25.49 |
| Revenue Next Year | N/A | $9.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 64.52 |
| 52 Week Low | $0.87 | $3.64 |
| 52 Week High | $3.40 | $8.77 |
| Indicator | ALEC | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 20.96 |
| Support Level | $1.87 | N/A |
| Resistance Level | $2.02 | $6.27 |
| Average True Range (ATR) | 0.14 | 0.28 |
| MACD | -0.03 | -0.08 |
| Stochastic Oscillator | 7.38 | 1.80 |
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.